ORIC

Oric Pharmaceuticals, Inc.

A clinical-stage biopharmaceutical company developing medicines to fight drug-resistant cancers. Its two lead drugs are rinzimetostat, a pill for advanced prostate cancer, and enozertinib, a brain-penetrating treatment for certain lung cancers, with trials run alongside partners Johnson & Johnson and Bayer. The company was founded in 2014 by top cancer researchers, and its name is an acronym for "Overcoming Resistance In Cancer."

CUSIP: 68622P109HealthcareUS2 holders

Ownership Activity Financials Filings

ORIC

ORIC

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Results of Operations and Financial Condition

Other Events

Results of Operations and Financial Condition

Other Events

Other Events